RINDBeRG試験におけるラムシルマブの投与タイミングにおけるサブグループ解析

Effects of an oral elemental nutritional supplement for gastric cancer with adjuvant S-1 therapy（Phase II trial: OGSG1108）

Neoadjuvant docetaxel, oxaliplatin, and S‑1 therapy for patients with large type 3 or type 4 gastric cancer: short‑term outcomes of a multicenter, phase II study (OGSG1902)

A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2‐positive Chemotherapy‐refractory Gastric Cancer (OGSG1203 HERBIS‐5): Final Results

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)

Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: a randomized clinical trial in third or further-line treatment of gastric cancer